References
- AbubakarIZignolMFalzonDDrug-resistant tuberculosis: time for visionary political leadershipLancet Infect Dis201313652953923531391
- World Health OrganizationGlobal Tuberculosis Report 2014Geneva, SwitzerlandWorld Health Organization20141171
- PinheiroMLúcioMLimaJReisSLiposomes as drug delivery systems for the treatment of TBNanomedicine (Lond)2011681413142822026379
- MullerRHMaderKGohlaSSolid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the artEur J Pharm Biopharm200050116117710840199
- MullerRHRadtkeMWissingSASolid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparationsAdv Drug Deliv Rev200254Suppl 1S131S15512460720
- MullerRHKeckCMChallenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticlesJ Biotechnol20041131–315117015380654
- MehnertWMaderKSolid lipid nanoparticles: production, characterization and applicationsAdv Drug Deliv Rev2001472–316519611311991
- SongXLinQGuoLRifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific deliveryPharm Res20153251741175125407545
- AristoffPAGarciaGAKirchhoffPDShowalterHDRifamycins – obstacles and opportunitiesTuberculosis (Edinb)20109029411820236863
- IracheJMSalmanHHGamazoCEspuelasSMannose-targeted systems for the delivery of therapeuticsExpert Opin Drug Deliv20085670372418532925
- RibeiroRDevelopment and Characterization of Nanocarrier Systems for the Delivery of Antitubercular DrugsPorto, PourtgalUniversidade do Porto2014
- JainAAgarwalAMajumderSMannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drugJ Control Release2010148335936720854859
- Urgently needed: new antibioticsLancet200937497051868
- VarshosazJEskandariSTabbakhianMFreeze-drying of nanostructure lipid carriers by different carbohydrate polymers used as cryoprotectantsCarbohydr Polym201288411571163
- DanhierFLecouturierNVromanBPaclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluationJ Control Release20091331111718950666
- PinheiroMPiscoSSilvaASNunesCReisSEvaluation of the effect of rifampicin on the biophysical properties of the membranes: significance for therapeutic and side effectsInt J Pharm20144661–219019724607210
- ChowAHTongHHChattopadhyayPShekunovBYParticle engineering for pulmonary drug deliveryPharm Res200724341143717245651
- ChoMChoWSChoiMThe impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticlesToxicol Lett2009189317718319397964
- MüllerHJacobsCKayserONanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the futureAdv Drug Deliv Rev200123131911251242
- DasSChaudhuryARecent advances in lipid nanoparticle formulations with solid matrix for oral drug deliveryAAPS PharmSciTech2011121627621174180
- KongJYuSFourier transform infrared spectroscopic analysis of protein secondary structuresActa Biochim Biophys Sin (Shanghai)200739854955917687489
- NimjeNAgarwalASaraogiGKMannosylated nanoparticulate carriers of rifabutin for alveolar targetingJ Drug Target2009171077778719938949
- KedmiRBen-ArieNPeerDThe systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activationBiomaterials201031266867687520541799
- KuninCMAntimicrobial activity of rifabutin, clinical infectious diseases: an official publication of the Infectious Diseases Society of AmericaClin Infect Dis199622Suppl 1S3S13 discussion S13–S148785253